A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome

Phase 2CompletedNCT01427816

Kissei Pharmaceutical Co., Ltd.180 enrolled

Overview

To evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndrome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

180

Conditions

Dry Eye Syndromes

Interventions

KCT-0809DRUG

PlaceboDRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Corneal and conjunctival damage * Insufficiency of lacrimal secretion * Ocular symptom Exclusion Criteria: * Severe ophthalmic disorder * Punctual plugs or surgery for occlusion of the lacrimal puncta

Locations (1)

Japan

Tokyo and Other Japanese City, Japan

Outcomes

Primary Outcomes

Corneal staining score

Time frame: 6 weeks

Secondary Outcomes

Conjunctival staining score

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.